LIGAND PHARMACEUTICALS (LGND)
US53220K5048 - Common Stock
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
7 Small-Cap Stocks for the Thinking Speculator
While these small-cap stocks may be miles away from Wall Street’s spotlight, they’re compelling enough to deliver some big surprises.
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ligand Pharmaceuticals Non-GAAP EPS of $1.05 beats by $0.39, revenue of $28.1M beats by $2.46M (NASDAQ:LGND)
Ligand Pharmaceuticals beats expectations with Q4 earnings, reporting higher Non-GAAP EPS and revenue.
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
Esai gets Japanese approval for epilepsy drug using Ligand technology (NASDAQ:LGND)
Ligand Pharmaceuticals (LGND) said Thursday that partner Esai (ESALF) (ESAIY) has received marketing authorization from Japanese regulators for an injected form
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
See How Ligand Pharmaceuticals Ranks Among Analysts' Top Picks With Strong Buyback Activity
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FDA approves Ligand's Zelsuvmi for treatment of molluscum (NASDAQ:LGND)
Ligand Pharmaceuticals (LGND) has received FDA approval for its topical gel Zelsuvmi for the treatment of molluscum contagiosum. Read more here.
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
Commit To Purchase Ligand Pharmaceuticals At $50, Earn 7.5% Annualized Using Options
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
Analyst Favorites With Strong Buyback Activity: Ligand Pharmaceuticals Ranks As a Top Pick
Ligand Pharmaceuticals Non-GAAP EPS of $1.02 beats by $0.40, revenue of $32.87M beats by $5.65M (NASDAQ:LGND)
Ligand Pharmaceuticals surpasses expectations in Q3 with a Non-GAAP EPS of $1.02 and revenue of $32.87M, beating estimates by $0.40 and $5.65M respectively.
Ligand Reports Third Quarter 2023 Financial Results
Ligand acquires royalty on Sanofi’s TZIELD for $20 million (NASDAQ:LGND)
Ligand Pharmaceuticals acquires Tolerance Therapeutics for $20 million in cash, gaining a less than 1% royalty on worldwide net sales of TZIELD.
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
Ligand To Report Third Quarter 2023 Financial Results On November 8
Ligand Pharmaceuticals Enters Oversold Territory (LGND)
Ligand Pharmaceuticals closes acquisition of assets of Novan (NASDAQ:LGND)
Biopharmaceutical company Ligand Pharmaceuticals successfully acquires the assets of bankrupt Novan, including berdazimer gel and NITRICIL™ technology, in a...
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
Ligand Appoints Martine Zimmermann to its Board of Directors
Top Buys by Directors: Davis's $237.5K Bet on LGND